Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dupilumab maintenance dose optimization in eosinophilic esophagitis
NL-OMON61544Phase 4Not yet recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Jul 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised trial of dupilumab in eosinophilic esophagitis (EoE) (2 arms), sponsored by Amsterdam University Medical Center. Primary endpoint: Maintenance of complete remission at Week 52. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
03
Conditions
eosinophilic esophagitis (EoE)
Beyond the preview
Go deeper on NL-OMON61544.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61544.